Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Bookmark and Share
Published: 19 Dec 2019
Views: 217
Rating:
Save
Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Dr Nadine Tung speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about a study evaluating cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative breast cancer.

She reports that the primary objective was the pathological complete response rate and contrary to expectations the rate for cisplatin was 18% and with doxorubicin/cyclophosphamide 26%.

Dr Tung reports that this was not significantly different perhaps meaning that BRCA deficiency or homologous recombination deficiency is more a marker of chemo-sensitivity to DNA damaging agents.